搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Desulfotomaculum reducens S-adenosylmethionine:tRNA ribosyltransferase-isomerase (queA) CSB-YP392181DHX
CSB-EP392181DHX
CSB-BP392181DHX
CSB-MP392181DHX
CSB-EP392181DHX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Desulfotomaculum reducens Dihydroorotate dehydrogenase B (NAD (+)), catalytic subunit CSB-YP392182DHX
CSB-EP392182DHX
CSB-BP392182DHX
CSB-MP392182DHX
CSB-EP392182DHX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Desulfotomaculum reducens UPF0296 protein Dred_1699 (Dred_1699) CSB-YP392183DHX
CSB-EP392183DHX
CSB-BP392183DHX
CSB-MP392183DHX
CSB-EP392183DHX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Desulfotomaculum reducens Adenylate kinase (adk) CSB-YP392184DHX
CSB-EP392184DHX
CSB-BP392184DHX
CSB-MP392184DHX
CSB-EP392184DHX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Desulfotomaculum reducens LexA repressor (lexA) CSB-YP392185DHX
CSB-EP392185DHX
CSB-BP392185DHX
CSB-MP392185DHX
CSB-EP392185DHX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Desulfotomaculum reducens (Dimethylallyl)adenosine tRNA methylthiotransferase MiaB CSB-YP392186DHX
CSB-EP392186DHX
CSB-BP392186DHX
CSB-MP392186DHX
CSB-EP392186DHX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Desulfotomaculum reducens Dihydrodipicolinate synthase (dapA) CSB-YP392187DHX
CSB-EP392187DHX
CSB-BP392187DHX
CSB-MP392187DHX
CSB-EP392187DHX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Desulfotomaculum reducens Proline--tRNA ligase (proS), partial CSB-YP392188DHX
CSB-EP392188DHX
CSB-BP392188DHX
CSB-MP392188DHX
CSB-EP392188DHX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Desulfotomaculum reducens ATP-dependent protease subunit HslV (hslV) CSB-YP392189DHX
CSB-EP392189DHX
CSB-BP392189DHX
CSB-MP392189DHX
CSB-EP392189DHX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Desulfotomaculum reducens NADH-quinone oxidoreductase subunit B (nuoB) CSB-YP392190DHX
CSB-EP392190DHX
CSB-BP392190DHX
CSB-MP392190DHX
CSB-EP392190DHX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Desulfotomaculum reducens 50S ribosomal protein L19 (rplS) CSB-YP392191DHX
CSB-EP392191DHX
CSB-BP392191DHX
CSB-MP392191DHX
CSB-EP392191DHX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Desulfotomaculum reducens 30S ribosomal protein S16 (rpsP) CSB-YP392192DHX
CSB-EP392192DHX
CSB-BP392192DHX
CSB-MP392192DHX
CSB-EP392192DHX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Desulfotomaculum reducens 50S ribosomal protein L28 (rpmB) CSB-YP392193DHX
CSB-EP392193DHX
CSB-BP392193DHX
CSB-MP392193DHX
CSB-EP392193DHX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Desulfotomaculum reducens Glutamate-1-semialdehyde 2,1-aminomutase (hemL) CSB-YP392194DHX
CSB-EP392194DHX
CSB-BP392194DHX
CSB-MP392194DHX
CSB-EP392194DHX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Desulfotomaculum reducens Xanthine phosphoribosyltransferase (xpt) CSB-YP392195DHX
CSB-EP392195DHX
CSB-BP392195DHX
CSB-MP392195DHX
CSB-EP392195DHX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Desulfotomaculum reducens Acetyl-coenzyme A carboxylase carboxyl transferase subunit beta (accD) CSB-YP392196DHX
CSB-EP392196DHX
CSB-BP392196DHX
CSB-MP392196DHX
CSB-EP392196DHX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Desulfotomaculum reducens DNA ligase (ligA), partial CSB-YP392197DHX
CSB-EP392197DHX
CSB-BP392197DHX
CSB-MP392197DHX
CSB-EP392197DHX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Desulfotomaculum reducens Carbon storage regulator homolog (csrA) CSB-YP392198DHX
CSB-EP392198DHX
CSB-BP392198DHX
CSB-MP392198DHX
CSB-EP392198DHX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Desulfotomaculum reducens DNA repair protein recO (recO) CSB-YP392199DHX
CSB-EP392199DHX
CSB-BP392199DHX
CSB-MP392199DHX
CSB-EP392199DHX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Desulfotomaculum reducens 30S ribosomal protein S21 (rpsU) CSB-YP392200DHX
CSB-EP392200DHX
CSB-BP392200DHX
CSB-MP392200DHX
CSB-EP392200DHX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來(lái)自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來(lái)產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來(lái)選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://www.pptc.cn/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>